Overexpression of microRNA‑203 can downregulate survivin and function as a potential therapeutic target in papillary thyroid cancer
- Xianjiang Wu
- Lei Dai
- Zhoujing Zhang
- Jueru Zheng
- Jianpei Zhao
Affiliations: Department of Thyroid Surgery, Ningbo No. 2 Hospital, Ningbo Medical University, Ningbo, Zhejiang 315010, P.R. China
- Published online on: November 13, 2019 https://doi.org/10.3892/ol.2019.11082
Copyright: © Wu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Papillary thyroid cancer (PTC) is the most common type of thyroid carcinoma. PTC has a considerably high five‑year survival rate; however, the possibility of recurrence is also high. Therefore, there is a requirement to clarify the molecular mechanism of PTC to promote understanding regarding the development of the disease and further improve prognosis. A number of studies have demonstrated that microRNAs (miRNAs or miRs) contribute to the progression of PTC. The present study revealed that the expression level of miR‑203 was significantly lower in PTC tissues and cell lines compared with in the normal controls. In addition, inhibition of miR‑203 was identified to be associated with an overexpression of survivin, which was observed in PTC samples. miR‑203 regulates the expression of Bcl‑2 via its downstream regulator survivin. Furthermore, the present study identified that inhibition of miR‑203 histone acetylation was associated with high expression levels of miR‑203 in PTC tissue samples. In summary, the results indicate that miR‑203 functions as a biomarker and may serve as a candidate target for the development of novel therapeutic strategies to treat PTC.